Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial

- Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, E. H., Watson, D. I., Ackland, S. P., Martin, J. M., Burge, M., Finch, R., Karapetis, C. S., Shannon, J., Nott, L. M., Varma, S., Marx, G., Falk, G. L., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G.

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

- Folprecht, G., Pericay, C., Ackland, S. P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J. R., Saunders, M. P., Thomas, A., Lopez Lopez, R., Roh, J. K., Chistyakov, V., Höhler, T., Kim, J. - S., Hofheinz, R. D.

Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis

- Garg, M. B., Lincz, L. F., Adler, K., Scorgie, F. E., Ackland, S. P., Sakoff, J. A.

The GOFURTGO study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

- Goldstein, D., Spry, N., Shapiro, J., Porter, I. W. T., Hruby, G., Horvath, L., Bydder, S., Underhill, C., Harvey, J., Gebski, V. J., Cummins, M. M., Brown, C., van Hazel, G. A., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S. P., Wratten, C.

Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo

- de Bock, C. E., Garg, M. B., Scott, N., Sakoff, J. A., Scorgie, F. E., Ackland, S. P., Lincz, L. F.